Reuters logo
BRIEF-FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501
2017年8月28日 / 下午1点14分 / 1 个月前

BRIEF-FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501

Aug 28 (Reuters) - La Jolla Pharmaceutical Co

* La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501

* La Jolla Pharmaceutical Co- ‍user fee goal date under prescription drug user fee act is February 28, 2018 for LJPC-501​

* La Jolla Pharmaceutical-‍in letter to co, FDA stated it does not currently plan to hold advisory committee meeting to discuss application for LJPC-501​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below